Verve Therapeutics Inc. (VERV)

Eli Lilly and Co (NYSE:LLY) is in advanced discussions to acquire Verve Therapeutics in a deal worth up to $1.3 billion, according to the Financial Times. The proposed terms include a nearly $1 billio...

Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.

Verve Therapeutics (VERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

From a technical perspective, Verve Therapeutics (VERV) is looking like an interesting pick, as it just reached a key level of support. VERV recently overtook the 200-day moving average, and this sugg...

The consensus price target hints at a 367.9% upside potential for Verve Therapeutics (VERV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago.

Equity markets have been volatile this year due to macroeconomic and geopolitical factors. Many of the world's largest corporations haven't escaped the sell-off, and it's hard to predict what's next.

Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (VERV 2.00%) big stock price leap this week. By the time the dust cleared, the biotech ...